BCIM
NBIX icon

British Columbia Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

British Columbia Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Buy
14,305
+565
+4% +$83.8K 0.02% 563
2026
Q1 		$1.81M Sell
13,740
-3,794
-22% -$503K 0.01% 623
2025
Q4 		$2.49M Buy
17,534
+3,310
+23% +$480K 0.01% 586
2025
Q3 		$2M Sell
14,224
-1,344
-9% -$182K 0.01% 588
2025
Q2 		$1.96M Sell
15,568
-3,795
-20% -$435K 0.01% 588
2025
Q1 		$2.14M Buy
19,363
+34
+0.2% +$4.31K 0.01% 605
2024
Q4 		$2.64M Buy
19,329
+2,543
+15% +$315K 0.02% 578
2024
Q3 		$1.93M Sell
16,786
-2,270
-12% -$311K 0.01% 615
2024
Q2 		$2.62M Buy
19,056
+7,326
+62% +$1M 0.02% 552
2024
Q1 		$1.62M Buy
11,730
+497
+4% +$67.9K 0.01% 613
2023
Q4 		$1.48M Buy
11,233
+2,444
+28% +$281K 0.01% 617
2023
Q3 		$989K Hold
8,789
– – 0.01% 638
2023
Q2 		$829K Buy
8,789
+230
+3% +$22.5K 0.01% 697
2023
Q1 		$866K Buy
8,559
+144
+2% +$15K 0.01% 682
2022
Q4 		$1.01M Sell
8,415
-919
-10% -$108K 0.01% 620
2022
Q3 		$991K Sell
9,334
-1,633
-15% -$166K 0.01% 648
2022
Q2 		$1.07M Sell
10,967
-3,678
-25% -$339K 0.01% 684
2022
Q1 		$1.37M Sell
14,645
-1,955
-12% -$166K 0.01% 728
2021
Q4 		$1.41M Sell
16,600
-887
-5% -$81.6K 0.01% 764
2021
Q3 		$1.68M Buy
17,487
+136
+0.8% +$12.8K 0.01% 731
2021
Q2 		$1.69M Buy
17,351
+2,820
+19% +$270K 0.01% 756
2021
Q1 		$1.41M Sell
14,531
-435
-3% -$45.6K 0.01% 740
2020
Q4 		$1.43M Sell
14,966
-335
-2% -$32.4K 0.01% 734
2020
Q3 		$1.47M Buy
15,301
+1,251
+9% +$145K 0.01% 672
2020
Q2 		$1.71M Buy
14,050
+4,479
+47% +$495K 0.02% 594
2020
Q1 		$828K Sell
9,571
-10,930
-53% -$1.07M 0.01% 616
2019
Q4 		$2.2M Buy
+20,501
New +$2.15M 0.02% 652

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

British Columbia Investment Management's NBIX Position: Q2 2026 in Review

British Columbia Investment Management increased its Neurocrine Biosciences (NBIX) stake by 4.1% in Q2 2026, buying an estimated $83.8K and bringing the position to 14,305 shares worth $2.41M. The position accounts for 0.02% of the portfolio, ranked #563.

British Columbia Investment Management first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.64M in Q4 2024. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • British Columbia Investment Management held 14,305 shares of Neurocrine Biosciences worth $2.41M as of Q2 2026.
  • British Columbia Investment Management bought 565 Neurocrine Biosciences shares in Q2 2026, an estimated $83.8K.
  • Neurocrine Biosciences made up 0.02% of British Columbia Investment Management's portfolio in Q2 2026, its #563 holding.
  • British Columbia Investment Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • British Columbia Investment Management's Neurocrine Biosciences position peaked at $2.64M in Q4 2024.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on British Columbia Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.